SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
FRA:56S1 - Deutsche Boerse Ag - FR0013154002 - Common Stock - Currency: EUR
We assign a fundamental rating of 4 out of 10 to 56S1. 56S1 was compared to 15 industry peers in the Life Sciences Tools & Services industry. 56S1 has only an average score on both its financial health and profitability. 56S1 is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
56S1 had positive earnings in the past year.
56S1 had a positive operating cash flow in the past year.
56S1 had positive earnings in each of the past 5 years.
56S1 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 2.12%, 56S1 is in line with its industry, outperforming 53.33% of the companies in the same industry.
56S1 has a Return On Equity (4.38%) which is comparable to the rest of the industry.
Looking at the Return On Invested Capital, with a value of 4.03%, 56S1 is doing worse than 60.00% of the companies in the same industry.
56S1 had an Average Return On Invested Capital over the past 3 years of 10.41%. This is above the industry average of 6.90%.
The last Return On Invested Capital (4.03%) for 56S1 is well below the 3 year average (10.41%), which needs to be investigated, but indicates that 56S1 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.12% | ||
| ROE | 4.38% | ||
| ROIC | 4.03% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
With a decent Profit Margin value of 6.29%, 56S1 is doing good in the industry, outperforming 80.00% of the companies in the same industry.
56S1's Profit Margin has declined in the last couple of years.
56S1 has a Operating Margin (13.32%) which is comparable to the rest of the industry.
56S1's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 43.40%, 56S1 is doing good in the industry, outperforming 66.67% of the companies in the same industry.
56S1's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.32% | ||
| PM (TTM) | 6.29% | ||
| GM | 43.4% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 56S1 is still creating some value.
The number of shares outstanding for 56S1 has been increased compared to 1 year ago.
The number of shares outstanding for 56S1 has been increased compared to 5 years ago.
The debt/assets ratio for 56S1 has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.83 indicates that 56S1 is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.83, 56S1 is in the better half of the industry, outperforming 73.33% of the companies in the same industry.
The Debt to FCF ratio of 56S1 is 6.04, which is on the high side as it means it would take 56S1, 6.04 years of fcf income to pay off all of its debts.
56S1's Debt to FCF ratio of 6.04 is in line compared to the rest of the industry. 56S1 outperforms 46.67% of its industry peers.
A Debt/Equity ratio of 0.70 indicates that 56S1 is somewhat dependend on debt financing.
56S1's Debt to Equity ratio of 0.70 is on the low side compared to the rest of the industry. 56S1 is outperformed by 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 6.04 | ||
| Altman-Z | 3.83 |
ROIC/WACC0.51
WACC7.88%
2.3 Liquidity
56S1 has a Current Ratio of 1.85. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
56S1 has a better Current ratio (1.85) than 86.67% of its industry peers.
56S1 has a Quick Ratio of 1.12. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.12, 56S1 is doing good in the industry, outperforming 73.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.97% over the past year.
56S1 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.19% yearly.
The Revenue has been growing slightly by 0.16% in the past year.
Measured over the past years, 56S1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.05% on average per year.
EPS 1Y (TTM)4.97%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%34.88%
Revenue 1Y (TTM)0.16%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%11.65%
3.2 Future
Based on estimates for the next years, 56S1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.34% on average per year.
The Revenue is expected to grow by 9.61% on average over the next years. This is quite good.
EPS Next Y23.98%
EPS Next 2Y25.51%
EPS Next 3Y24.81%
EPS Next 5Y19.34%
Revenue Next Year9.64%
Revenue Next 2Y10.58%
Revenue Next 3Y10.89%
Revenue Next 5Y9.61%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 49.38 indicates a quite expensive valuation of 56S1.
66.67% of the companies in the same industry are cheaper than 56S1, based on the Price/Earnings ratio.
56S1's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.33.
With a Price/Forward Earnings ratio of 34.03, 56S1 can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, 56S1 is valued a bit more expensive than the industry average as 60.00% of the companies are valued more cheaply.
56S1's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.37.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.38 | ||
| Fwd PE | 34.03 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 73.33% of the companies listed in the same industry.
56S1's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.43 | ||
| EV/EBITDA | 30.41 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
56S1's earnings are expected to grow with 24.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.06
PEG (5Y)11.77
EPS Next 2Y25.51%
EPS Next 3Y24.81%
5. Dividend
5.1 Amount
With a yearly dividend of 0.37%, 56S1 is not a good candidate for dividend investing.
56S1's Dividend Yield is slightly below the industry average, which is at 0.92.
With a Dividend Yield of 0.37, 56S1 pays less dividend than the S&P500 average, which is at 2.51.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.37% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
56S1 pays out 38.39% of its income as dividend. This is a sustainable payout ratio.
56S1's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP38.39%
EPS Next 2Y25.51%
EPS Next 3Y24.81%
FRA:56S1 (4/22/2025, 7:00:00 PM)
187.65
+14.9 (+8.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.63%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.26B
Analysts76.67
Price Target254.89 (35.83%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.37% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP38.39%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.01%
Min EPS beat(2)-5.62%
Max EPS beat(2)7.63%
EPS beat(4)1
Avg EPS beat(4)-6.92%
Min EPS beat(4)-20.27%
Max EPS beat(4)7.63%
EPS beat(8)1
Avg EPS beat(8)-19.76%
EPS beat(12)1
Avg EPS beat(12)-20.47%
EPS beat(16)5
Avg EPS beat(16)-12.49%
Revenue beat(2)1
Avg Revenue beat(2)-1.1%
Min Revenue beat(2)-5.11%
Max Revenue beat(2)2.91%
Revenue beat(4)2
Avg Revenue beat(4)-2.22%
Min Revenue beat(4)-8.16%
Max Revenue beat(4)2.91%
Revenue beat(8)3
Avg Revenue beat(8)-1.91%
Revenue beat(12)4
Avg Revenue beat(12)-1.2%
Revenue beat(16)8
Avg Revenue beat(16)12.76%
PT rev (1m)-0.78%
PT rev (3m)14.23%
EPS NQ rev (1m)2.58%
EPS NQ rev (3m)16.05%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)-0.27%
Revenue NQ rev (1m)-0.27%
Revenue NQ rev (3m)0.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.38 | ||
| Fwd PE | 34.03 | ||
| P/S | 6.57 | ||
| P/FCF | 38.43 | ||
| P/OCF | 22.41 | ||
| P/B | 4.58 | ||
| P/tB | N/A | ||
| EV/EBITDA | 30.41 |
EPS(TTM)3.8
EY2.03%
EPS(NY)5.51
Fwd EY2.94%
FCF(TTM)4.88
FCFY2.6%
OCF(TTM)8.37
OCFY4.46%
SpS28.56
BVpS40.96
TBVpS-5.68
PEG (NY)2.06
PEG (5Y)11.77
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.12% | ||
| ROE | 4.38% | ||
| ROCE | 5.06% | ||
| ROIC | 4.03% | ||
| ROICexc | 4.45% | ||
| ROICexgc | 14.12% | ||
| OM | 13.32% | ||
| PM (TTM) | 6.29% | ||
| GM | 43.4% | ||
| FCFM | 17.1% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexcg growth 3Y-36.77%
ROICexcg growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 6.04 | ||
| Debt/EBITDA | 4.17 | ||
| Cap/Depr | 112.63% | ||
| Cap/Sales | 12.22% | ||
| Interest Coverage | 2.09 | ||
| Cash Conversion | 121.31% | ||
| Profit Quality | 271.91% | ||
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 3.83 |
F-Score5
WACC7.88%
ROIC/WACC0.51
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)4.97%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%34.88%
EPS Next Y23.98%
EPS Next 2Y25.51%
EPS Next 3Y24.81%
EPS Next 5Y19.34%
Revenue 1Y (TTM)0.16%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%11.65%
Revenue Next Year9.64%
Revenue Next 2Y10.58%
Revenue Next 3Y10.89%
Revenue Next 5Y9.61%
EBIT growth 1Y-17.48%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year85.65%
EBIT Next 3Y36.02%
EBIT Next 5Y24.38%
FCF growth 1Y74.23%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y9.2%
OCF growth 3Y5.11%
OCF growth 5Y21.32%